inclusion criteria: * japanese men and women and 18 to 55 years of age inclusive, at the time of signing the informed consent. * no positive results of sars-cov-2 nat and/or rapid antigen tests. * healthy participants by medical history, physical examination, baseline safety laboratory studies, and screening parameters, according to the judgement of the investigators, with no concomitant disease or concomitant medication. * ecg without clinically significant abnormalities. * able to complete the follow-up period through day 361 as required by the protocol. * body weight ≥ 45 kg and ≤ 110 kg and bmi ≥ 18.0 to ≤ 30.0 kg/m2.

inclusion criteria: * japanese men and women and 18 to 55 years of age inclusive, at the time of signing the informed consent. * no positive results of sars-cov-2 nat and/or rapid antigen tests. * healthy participants by medical history, physical examination, baseline safety laboratory studies, and screening parameters, according to the judgement of the investigators, with no concomitant disease or concomitant medication. * ecg without clinically significant abnormalities. * able to complete the follow-up period through day 361 as required by the protocol. * body weight ≥ 45 kg and ≤ 110 kg and bmi ≥ 18.0 to ≤ 30.0 kg/m2.

inclusion criteria: japanese men and women and 18 to 55 years of age inclusive, at the time of signing the informed consent. no positive results of sars-cov-2 nat and/or rapid antigen tests. healthy participants by medical history, physical examination, baseline safety laboratory studies, and screening parameters, according to the judgement of the investigators, with no concomitant disease or concomitant medication. ecg without clinically significant abnormalities. able to complete the follow-up period through day 361 as required by the protocol. body weight ≥ 45 kg and ≤ 110 kg and bmi ≥ 18.0 to ≤ 30.0 kg/m2.

inclusion criteria: japanese men and women and 18 to 55 years of age inclusive, at the time of signing the informed consent. no positive results of sars-cov-2 nat and/or rapid antigen tests. healthy participants by medical history, physical examination, baseline safety laboratory studies, and screening parameters, according to the judgement of the investigators, with no concomitant disease or concomitant medication. ecg without clinically significant abnormalities. able to complete the follow-up period through day 361 as required by the protocol. body weight ≥ 45 kg and ≤ 110 kg and bmi ≥ 18.0 to ≤ 30.0 kg/m2.